1Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation:evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation[J]. Acta Cardiol, 2001, 56(6) :375-380.
2Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillgtion[J]. Circulation, 2001,104(24) : 2886-2891.
3Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation[J]. Circulation, 2003, 108 (24):3006-3010.
2[2]Goette A, Honeyeutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation, 1996,94: 2968-2974.
3[3]Everett TH, Li H, Mangrum JM, et al. Electrical morphological,and ultrastructual remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation, 2000, 102: 1454-1460.
4[4]Ausma J, Disspersyn G, Duimel H, et al. Changes in ultrastructum distribution in goat atrium during atrial fibrillation. J Medicine,2000, 32: 342-355.
5[5]Frustaci a, Chimenti C, Bellocci F, et al. Histological subusbiopsies in patient with lone atrial fibrllation. Circulation, 2002,337-351.
6[6]Kostin S, Klein G, Szalay Z, et al. Structural correlate of a in human patients. Cardio Res, 2002, 54: 361-379.
7[7]Goette A, Staack T, Rochen C, et al. Increased expression signal converting enzyme in human atria during atrial fibrilltion. Cardiol,2000, 35: 1669-1677.
8[8]Bmndel BJ, Ausma J, Gelder I, et al. Activation of proteoly and structural changes in human paroxysmal and persistent atrial fibrillation. Cardio Res, 2002, 54: 427-437.
9[9]Dilisa F, De Tullio R, salamino F, et al. Specific degradation and I by calpain and tissue modulation by substrate phosphryla.CardiolJ, 1995, 308: 57-61.
10[10]Arndt M, Lendekel U, Rocken C, et al. Altered Expression disintegrin and metalloprotienase in fibrillation human atria. Cardiol,2002, 105: 720
2Oliver Adam, Hans - Ruprecht Neuberger, Michael B. hm andUlrich Laufs. Prevention of Atrial Fibrillation with 3 - Hydroxy - 3 - Methylgiutary| Coenzyrae A Reductase lnhibitors [ J ]. Cir- culation, 2008, 118:1 285 - 1 293.
3Liao JK, Laufs U. Pleiotropic Effects of S'tatins[J]. Annu Rev Pharrnacol T0xicol, 2005, 45 (89) : 118.
4Link A, Ayadhi T, Niekenig G. Rapid immunomodulation by ro- suvastatin in patients with acute eoronary syndrome [ J ]. Eur Heart J, 2006, 27:2 945 - 2 955,.
5Ridker PM, Cannon CP, Morrow D, et al. C - reactive protein levels and outcomes after statin therapy [ J ]. N Engl J Med, 2005, 352:20 - 28.
6Hoffmann S. Incidence and diagnosis of acute rhematic fever in Denmark, 1980 and 1983. Retrospective analysis of the fulfillment of the revised Jones criteria in hospiatalited patients [ J ]. Actamedica Scadn, 1994,15 ( 2 ) :56-56.
7Ansell B J, Fonarow G C, Navab M, et al. Modifying the anti- inflammatory effects of high-density lipoprotein [ J 1. Curt Athemseler Rep ,2007,9:57-63.
